FTC, states sue WPATH over transgender youth treatment guidelines

The Federal Trade Commission and four Republican-led states accused the World Professional Association for Transgender Health of helping medical providers mislead parents about transgender youth treatment, turning a consumer-protection case into a direct challenge to the field’s most cited clinical guidance. The complaint filed in federal court in Texas centered on puberty blockers, hormones and surgery for minors with gender dysphoria.

WPATH, a 501(c)(3) nonprofit professional and educational group, said its Standards of Care 8 were built by a multidisciplinary team of clinicians, researchers and stakeholders and published in September 2022 as the organization’s official guidance. The current version followed the original standards, first issued in 1979, and SOC-7, published in 2012. The FTC alleged WPATH omitted age limits for breast amputation and penis removal in SOC-8 and failed to disclose side effects of some cross-sex hormones.

The agency’s theory reaches beyond one organization. Because SOC-8 serves as a clinical reference point for doctors treating transgender and gender-diverse patients, a federal finding that WPATH helped disseminate deceptive claims could reverberate through treatment protocols well beyond the five parties now in court. That could matter for providers and insurers that look to specialty guidelines when determining what care is medically appropriate, especially in a field where national standards have been heavily contested by lawmakers and regulators.

The lawsuit also marked a break from earlier transgender-care battles. Instead of focusing on state bans, licensing disputes or constitutional claims alone, the FTC invoked federal consumer-protection power and said WPATH supplied the means for false and unsubstantiated claims to parents in order to sell pediatric medical transition services. WPATH rejected that argument, saying the FTC is not a medical provider, has no place interfering in individualized medical decision-making and lacks jurisdiction over its noncommercial speech.

The case grew out of a fast-moving legal fight. On Jan. 15, 2026, the FTC issued WPATH a civil investigative demand. WPATH filed suit in Washington, DC, on Feb. 18, saying the probe violated the First and Fourth Amendments and exceeded the agency’s authority over a nonprofit. The FTC denied WPATH’s petition to quash the demand on March 24 before joining Alaska, Iowa, Nebraska and Texas in the Texas lawsuit on Tuesday.

The dispute lands amid a broader Trump administration and Republican-led state push against gender-affirming care for minors. Major medical groups have continued to describe the treatment as evidence-based, including the Endocrine Society, whose 2017 guideline was co-sponsored by WPATH, and the American Academy of Pediatrics, which reaffirmed its support in August 2023 and later authorized a systematic review after more than 20 states enacted bans.